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Abstract Kidney cysteine conjugate i~-lyase (glutamine tran- 
saminase K, kyneurenine aminotransferase, EC 2.6.1.64) 
metabolises the cysteine conjugates of certain halogenated al- 
kenes and alkanes to form reactive metabolites which can produce 
nephrotoxicicity and neurotoxicicity in experimental animals and 
man. Using a combination of hybridisation screening and PCR 
techniques we have isolated a full-length cDNA for human kidney 
cysteine conjugate i~-lyase. Comparison of the deduced amino 
acid sequence with that of the rat enzyme indicated an 82% 
overall similarity, with 90% similarity around the pyridoxal phos- 
phate binding site, many of the changes being conservative in 
nature. Expression of the cDNA in Cos-1 cells resulted in the 
production of a cytosolic enzyme which showed both cysteine 
conjugate ~-lyase and glutamine transaminase K activity. Pre- 
liminary mapping of the gene for human cysteine conjugate ~- 
lyase by PCR analysis of genomic DNA from human-rodent 
hybrid cells indicated that it is located on human chromosome 9. 
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I. Introduction 
Many halogenated xenobiotics are detoxified by conjugation 
to glutathione [1]. Subsequent metabolic processing yields the 
cysteine conjugate of the original chemical which may then 
serve as a substrate for enzymes that express fl-lyase activity [1]. 
In rat and human kidney this activity is expressed by a specific 
form of cysteine conjugate fl-lyase (glutamine transaminase K, 
GTK, EC 2.6.1.64) resulting in the production of metabolites 
which in the rat are toxic to the P3 segment of the renal prox- 
imal tubule [2]. In man, however, while abnormality of kidney 
function has been observed in workers exposed to the dry- 
cleaning fluid perchloroethylene [3], nephrotoxicity similar to 
that in the rat has not been reported following exposure to 
halogenated compounds which can be metabolised via the cys- 
teine conjugate fl-lyase pathway. Rather, excessive xposure in 
man to halogenated alkenes can result in neurotoxicity and 
neurodegeneration [4,5]. The reason for this difference in re- 
sponse between rat and man is not yet clear. It is known that 
cysteine conjugate fl-lyase/GTK is present in brain [6] where its 
function may be related to ammonia metabolism [6]. However, 
the finding that the enzyme also possesses kyneurenine amino 
transferase (KAT) activity [7] raises the possibility that it may 
play a role in neurotransmission viamodulation of the NMDA 
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receptor [8]. Thus the neurotoxicity of some halogenated al- 
kenes in man may be related to the specific localisation of 
cysteine conjugate fl-lyase/GTK/KAT in specific neurons and 
the localised effects of toxic metabolite production. As an ap- 
proach to studying this enzyme in man we now report the 
isolation and characterisation f a eDNA clone containing the 
complete coding region of human kidney cysteine conjugate 
fl-lyase. 
2. Materials and methods 
2.1. Hybridisation screening of a human kidney cDNA library 
A human kidney 5'-stretch eDNA library in )t,gt 10 (HL1123a, Clon- 
tech Laboratories Inc., Palo Alto, USA) was screened by hybridisation 
with a probe derived from the full-length rat kidney cysteine conjugate 
fl-lyase eDNA described previously [9]. A total of 1 x 10 6 plaques were 
screened under stringent conditions of hybridisation. Phage DNA from 
9 positive plaques was digested with EcoRI and the cDNA insert sizes 
assessed by gel electrophoresis. The cDNA inserts were extracted and 
re-cloned in the plasmid vector pGEMzf(+) for sequencing and further 
analysis. DNA sequencing on both strands was performed by the did- 
eoxy chain termination method using the Sequenase v rsion 2.0 system 
(Amersham Life Science, Amersham, UK). The largest (1.5 kb) human 
fl-lyase cDNA fragment containing an open reading frame was named 
ph,81-1. Further screening of the library by hybridisation to ph/~l-ldid 
not produce a full-length cDNA clone (expected minimum size 1.7 kb) 
or one containing the 5' end of the cDNA. Interestingly, one of the 
clones from the original screening contained an intronic sequence prior 
to nucleotide 231 of the phfll-1 cDNA sequence, with a splice acceptor 
site at that position. 
2.2. 5'-RACE amplification and cloning 
The missing 5' end of the human fl-lyase cDNA sequence was isolated 
using the 5'-rapid amplification of cDNA ends (5'-RACE) procedure 
[10] with human kidney 5'-RACE-ready cDNA (Clontech Laboratories 
Inc.). A primary PCR amplification was performed using a 3' oligonu- 
cleotide primer corresponding to nucleotides 468 to 483 of phfll-1, and 
the 5' anchor primer provided with the Clontech Inc kit. After 30 
rounds of amplification using the manufacturer's recommended proce- 
dure, an aliquot of the primary reaction was used in a second PCR 
amplification using a nested 3' oligonucleotide primer corresponding 
to nucleotides 358 to 377 of phfll-1 and the anchor primer provided with 
the kit. PCR products were sized by electrophoresis, extracted, and 
subcloned into the TA Vector pCRII (Invitrogen R & D Systems 
Europe Ltd, Abingdon, UK) for DNA sequencing. The longest over- 
lapping human fl-lyase eDNA fragment (0.4 kb) which included the 
putative start of the coding sequence was named plafll-2. 
2.3. RT-PCR amplification of full-length uman kidney ~-lyase cDNA 
Total RNA was extracted from a human kidney sample using 
RNAzol B (Biogenesis Ltd, Poole, UK), as per the manufacturer's 
instructions. First strand cDNA synthesis was performed with reverse 
transcriptase (Life Technologies, Paisley, UK), according tothe manu- 
facturer's recommended procedure, using a 3' oligonucleotide primer 
corresponding to nucleotides 1,480 to 1,499 ofphfll-1. PCR amplifica- 
tion of the first strand product was performed using a second, nested 
3' primer corresponding to nucleotides 1,338 to 1,357 and a 5' primer 
corresponding to nucleotides 30 to 45 of phfll-2. The 1.3 kb PCR 
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I GGGG TG AAGCGGCC CAGGTGABGC TCGCC 
30 AT(; GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC T6G 6TG GAG TTT GTG AAA HUMAN 
Met AIO Ly ;  Gin Leu Gin A la  Arcj Arg Leu Asp GI V l i e  Alp Tyr ASh Pro T ip  Vat Glu Phe Vo! Lys ~3 
Q Thr  • A~J • • • • • • • • • • G J n • Leu • • • • 61V • RAT 
99 CTG ~'C AGT GAG CAT GAC GTC GTG AAC TTG GGC CAG EEC TTC CCG GAT TTC CCA CCA CCA GAC XTT GCC HUI~M 
Leu A la  See" GIU HIS Asp V¢ll Val Ash Leu Gly Gin G ly  Pile Pro Asp Phe Pro  Pro Pro As;p Phe A la  q6 
• Thr Lys • TyP • • • • • • • • • • • • SeP • • Q • • RAT 
168 GTE; GAA GCC !rfT CAG CAC GCT 6TC AGT GGA EAC TTC AT(; CTT AAC CA(; T&C ACC AAG ACA T~T GGT TAC HUMAN 
VOI 61u A la  Phe Gin HIS AIo Vat Ser S ly  Asp Phe Net Leu Ash ( ; In Tyr  Thr  Lys Thr  Phe Gly Tyr  69 
Thr 81n • • • Gin • Thr • • Ash • • • • • • • Ar 9 A la  • • • RAT 
237 CCA CCA CTG ACE AAG ATC CT6 GCA AGT TTC TTT GGG GAG CTG CTG GGT CA(; GAG ATA 6AC CCG CTC AGG HUMAN 
Pro PrO Leu Thr Lys | le  Let] A la  Set Phe Phe GIy GIu Leu Leu 6;ly Gin Glu  | le  A lp  Pro Leu AP 9 ~2 
• • • • Aen Vol • • • • • • Lye • • • • • Met • t • Thr RAT 
306 AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG GCC CTG TTC ACA GCC TTC CA(; GCC CTG 6TG GAC GAA GGA HUHAN 
ARn Val Leu Val Thr" Val Gly 8 Iv  Tyr  GIy A la  Leu Phe Thr  AJa Phe Gin  AIo Leu Va! Asp 61u 81y 115 
• • • • • • • AIo • • • • • • Ar~ • • e • • • • • RAT 
37~J GAC GAG 6TC ATC ATC ATC GAA CCC TTT TTT GAC T6C TAC 6AG CCC ATE ACA ATG ATG 6CA GG6 GGT C6T HUtlAN 
Asp Glu Vol | l e  l i e  l i e  61u Pro Phe Phe Asp Cys Tyr  Glu Pro Met Thr  Met Pet AIo G ly  Gly Arg 138 
• • • • • Het • • AIO • • • • • • • • Q • • • • Cys RAT 
qqtl CCT 6TG rTT GTG TCC CTG AAG CCG 6GT CCC ATC CAG AAT GGA 8AA CTE GET TCC AGC AGC AAC T66 CAG HUMAN 
Pro Vol Phe Vol Set Leu Lys Pro Gly  Pro l i e  Gin Asn GIy GIu Leu E ly  Set SeP Set Ash Trip Gin 16| 
• • • • ThP • • • Sei" • A la  Pro Lys • Ly~ • • A la  • Asn Asp • • RAT 
513 CTG GAC CCC ATG GAG CTG GCC GGC AAA TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC HUttAN 
Leu Asp Pro blet GIu Leu AIo G iy  Lys Phe ]hr  Set" Ap 9 Thr  Lye; A Io  Leu Vc~I Leu Ash Thr  pro Ash 18tt 
• • • A la  • • • SeP • • • Pro • • • | le  • ~ • • • • • RAT 
582 AAC CCC CTG GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG CAG CAT GAC HUMAN 
Ash Pro Leu GIy Lys Vol Phe Set APO Glu Glu Leu Glu Leu Val A la  Ser Leu Cys Gin  Gin His ASp ~07 
• • • • • • • • • Met • • • • • • ASh Q • • • • • RAT 
651 GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGE ATG GTC TAC SAC GGG CA t` CA(; CA(: ATC AGC ATT GCC HUMAN 
Val Vol Cys l i e  The" Asp Glu Vol Tyr Gin T ip  Met Vol Tyr  Asp G ly  H is  Gin H is  l i e  Set l i e  A la  ~30 
• • • • SeP • • • • • • Leu • • • • • • • Vo l  • • • RAT 
I 1 . . . "  ,o  . . .  - -  . • . ,  . , .  • • ,o  • • • . o  . • . - -  
"7a9 TGG AAG 6TG GGC TGG GTC CTG (;GT CCA GAT CAC AT[~ ATG AAG CAC CTG CG r; ACC GI"G CAC CA6 AAC TCC HUMAN 
Tip Ly$ Vat G ly  Trp Vol Lem S ly  Pro Asp His  l i e  Met I-ys H is  Leu Ar~ The" Vol H is  Gin Ash Seer- 276 
• • • • e • 14et • e • AGn e • • • • • ~ • • • • • RAT 
855 GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA GCC GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC HUMAN 
Vol Phe His Cys Pro Thr Gin Set GIh AIo AIo Vol AIo Glu Set Phe Glu Ar  9 Gtu Gin  Leu Leu Phe 299 
[ le  • • • • • • AIo • • • • • Gin Cye • • o • • Gin His • RAT 
927 CGC CAA CCC AGC AGC TAC TTT GTG CAG TTC CCG CAG 6CC ATG CAG CGC TGC CGT GAC CAC AT6 ATA CGT HUMAN 
AI-(j Gin Pro Set- Set Tyr  Phe Vol Gin Phe Pro Gin AIo Het Gin AP~ Cys Ap 9 Asp H is  Met l i e  APcj 322 
Giy • • • • • • Leu • Leu • • • • Glu Leu Ash • • • • • • RAT 
9Q5 AGC CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC CTC A¥C ACA GAC ATC TCA HUMAN 
SeP Leu Gin Set" Vol G ly  Leu Lys Pro l i e  | le  PPO Gin Gly See" Tyr  Phe Leu l ie  Thr  Asp l ie  See" 3q5 
• • • • • • • • Leu TPp • Set • • t • • • • AIo • • • RAT 
1065 GAC TTC AAG AGG AAG ATG CCT GAG TTG CCT GGA GCT 6TG GAT GAG CCC TAT GAC AGA CGC T(C GTC AAG HUHAN 
Asp Phe LVS Ar~ Lys Ret Pro Asp Leu Pro 61y A la  Vol Asp Glu Pro  Tvr" Agp AP 9 Ar<j Phe Val Lys 368 
• • • Set • • • • • • • • GIu e • • • • • • • AIo • RAT 
113LI TGG ATG ATC AAG AAC AAG GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG AAS HUHAN 
Trp Met | le  Lys Asn Lys Gly Leu Val A|cl l i e  PPO Vol Set l i e  Phe Tyr" Set Vol Pro H;s  Gin Lys 391 
• • • • • Met • • • GIy • • • • Thr" • Phe t Arg • • • • RAT 
1203 CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC AC6 CTC CAG ECC ATG GAC GAG AAG HUIIAN 
Hi~ Phe ASp HIS Tyr" l i e  Arg Phe CyS Phe Val Lys Asp Glu A la  Thr  Leu Gin A la  Pet Asp Glu LVS q lq  
Asp • • • • • • • • • • • • LyS • • • e • • • • Arg RAT 
1272 CTG CGG AAG TGG AA6 GTG GAA CTC TAG CCCTGAAGTCACGCCTTGGCCCTGACATCCCCACATGCCCGCAGAGATCCTCTTT HUMAN 
LI~J Ar" 9 LVS Trp Lys Val Glu Leu Stop q22 
• • • • • GIu Leu Kin Pro Stop q23 RAT 
13JSq GAGTGTC TGTC TTTG TCC AGGTTTC AGACATTTCTAGGTTGGGGAA6ATGCTATTGGGAAACC TC TTC TCCGTGACACAGAATGT TCTGGG HUHAN 
Iq45 TGGGAGCCGCCC TTC ~C ATCYTAGAGAACCAAGTGCC TCCTGTC TGAAAGGTGAGGGTGGCC TGACCTGGGCCTCTCCCTGCCCCTCCAT HUI4AN 
1535 AG~TGGGTTTGTAGGGTCTfGTGTTGCTTCTGGTCTCTCCAGGCTTGGCTGAGACGGACGGTAGACTT¢CACCATGTACCGATCACATCCC HtYeIAN 
1627 AGCTCTG~ATG~CCCCT~CTAAGGCTCA~GTATA&~CTCACCTTCCCT~CTCATCTTGGCCTTGGGGAGTTGCCTTTA6G~TG ~7|0 HUMAN 
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2.4. Expression of the human ~-lyase cDNA in Cos-1 cells 
The full-length uman fl-lyase cDNA insert from phfll-3 was excised 
with EcoRI and inserted into the expression vector pUS1000 [9]. The 
insert orientation relative to the CMV promoter of transcription i the 
vector was confirmed by digestion with ApaI (data not shown). Trans- 
fection of plasmid DNA into Cos-1 cells, preparation of cellular ex- 
tracts, and measurement of both glutamine transaminase K andfl-lyase 
enzyme activities was as described before [9]. 
2.5. Chromosome assignment of the human kidney ~-lyase gene 
Genomic DNA from a series of rodent-human somatic ell hybrids 
(a gift from Dr. Lesley Rooke, Imperial Cancer Research Fund, Lon- 
don, UK) was analysed for the presence offl-lyase sequences u ing a 
3' primer corresponding to nucleotides 468 to 483 of the phfll-1 se- 
quence, and a 5' primer corresponding to 16 nucleotides of intronic 
sequence 426 bases upstream of the splice site at nucleotide 231 of the 
sequence• PCR products were run on an agarose gel to separate the 
human-specific product from that of the rodent background. The 
authenticity ofthe PCR products was confirmed by Southern blotting 
and hybridisation to the full-length ~-lyase cDNA. 
3. Results and discussion 
A composite sequence for human kidney fl-lyase DNA was 
assembled from the overlapping clones phfll-1 and phfll-2 (Fig. 
la) and confirmed by sequencing of phfll-3. The open reading 
frame (Fig. lb) codes for a polypeptide of 422 amino acids 
which has an overall similarity of 82% with rat kidney cytosolic 
fl-lyase and a similarity of 90% in the region (amino acids 185 
to 287) spanning the putative pyridoxal phosphate (PLP) bind- 
ing site. The deduced subunit molecular weight of the human 
kidney fl-lyase apoprotein is 47.9 kDa. Of the 78 amino acid 
sequence differences between the rat and human orthologues 
of this protein, 23 are conservative in nature. 
The insert cDNA sequence from phfll-3 was recloned into a 
mammalian expression vector and transfected into Cos-1 cells. 
As shown in Fig. 2, a significant increase in both glutamine 
transaminase K and cysteine conjugate,fl-lyase ctivity was seen 
in cells transfected with the cDNA in the sense orientation 
relative to the promoter of mRNA synthesis. A preliminary 
estimate (data not shown) of the Km for the human fl-lyase 
activity expressed in Cos-1 cells, using S-(1,1,2,2-tetra- 
fluoroethyl)-L-cysteine as substrate, indicated that at 6.5 mM 
it corresponded closely with that measured for the rat enzyme 
expressed in the same cells (5.2 mM). This finding suggests that 
any species differences in kidney toxicity of halogenated alk- 
enes between rat and man must be attributable to the amount 
of cysteine conjugate fl-lyase enzyme in kidney proximal tubule 
cells, or other factors uch as the uptake of cysteine conjugates 
into the cells, rather than to marked differences in kidney 
fl-lyase enzyme kinetics or substrate specificity. 
Analysis of genomic DNA from somatic ell hybrids for the 
presence of human kidney fl-lyase sequences by PCR indicated 
that whereas a 0.7 kb band of rodent origin was obtained from 
all samples, only hybrid GM10611 which contained human 
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product was purified by gel electrophoresis, extracted, cloned into 
pCR II for DNA sequencing and named phfll-3. 
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Fig. 2. Enzyme activity in cytosolic extracts of Cos-1 cells transfected 
with the human fl-lyase cDNA (ph/31-3). (a) Glutamine transaminase K, 
(b) Cysteine conjugate fl-lyase activity using S-(1,2-dichlorovinyl)-L- 
cysteine (DCVC) and S-(1.1.2.2-tetrafluoroethyl)-L-cysteine (TFEC) as 
substrates. 
chromosome 9 as the sole human genetic ontribution, gave an 
additional PCR band of 1.0 kb. This latter band gave a strong 
signal when hybridised to the radiolabelled cDNA insert from 
phfll-3 (Fig. 3). An identical band was observed when total 
human genomic DNA was subjected to PCR using the same 
primers (data not shown) Experiments are in progress to con- 
firm the presence of the human kidney fl-lyase gene locus on 
chromosome 9 and to map its location. In conclusion, the 
availability of a cDNA for human kidney cysteine conjugate 
fl-lyase/GTK/KAT will enable further study on fl-lyase medi- 
ated toxicity of halogenated alkenes in man and the role of 
KAT in the modulation of neurotransmission via the NMDA 
receptor. 
<__ 
Fig. 1. Human kidney cysteine conjugate fl-lyase cDNA. (a) Overlapping human fl-lyase cDNAs referred to in the text, (b) sequence omposite of 
the overlapping 5'and 3' cDNAs from phfll-2 and phfll-1, confirmed between nucleotides 30 and 1357 by subsequent sequencing of the cDNA insert 
from phfll-3. The primer sequences u ed to produce the full-length cDNA, phfll-3, by RT-PCR are underlined. The concensus pyridoxal phosphate 
binding site is boxed. Amino acid differences from rat kidney cytosolic cysteine conjugate fl-lyase [9] are shown below the human sequence; e, indicates 
amino acid identity. 
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Fig. 3. Preliminary chromosomal ssignment of human fl-lyase. PCR 
products from amplification of rodent-human hybrid cell DNA using 
fl-lyase specific primers were electrophoresed on an agarose gel, trans- 
ferred to nylon membrane and hybridised to the human fl-lyase cDNA 
probe (phfll-3). A human-specific band is seen only in lane 9 corre- 
sponding to the human chromosome 9-containing hybrid, GM10611. 
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